Loading stock data…
BFRI
$0.88-0.05 (-5.73%)
Pre-Market$0.88-0.00 (-0.03%)· Last close Jun 9
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biofrontera Inc. in the Healthcare sector is trading at $0.88 with a market capitalization of $11M. Wall Street consensus targets $5.88 (2 analysts), implying a +567.6% move over the next 12 months. The stock is currently 26% below its 52-week high of $1.19, remaining 3.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +567.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.08M↓ | $17.10M↑ | $6.99M↓ | $9.03M↑ | $8.59M |
| Gross Profit | $7.97M↓ | $14.09M↑ | $4.94M↓ | $6.39M↑ | $5.32M |
| Operating Income | -$3.93M↓ | $4.56M↑ | -$6.28M↓ | -$5.08M↓ | -$4.55M |
| Net Income | -$4.75M↓ | $5.64M↑ | -$6.65M↓ | -$5.32M↓ | -$4.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.27M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-182.62%
Volume
Today's trading volume
184,634
Recent News
Biofrontera (BFRI) Q1 2026 Earnings Transcript
All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in Biofrontera's press releases and SEC filings, including the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026, and the company's annual report on Form 10-K for the year ended December 31, 2025. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law.
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Biofrontera Inc (BFRI) reports a 17% revenue increase and significant margin expansion, while navigating increased expenses and regulatory uncertainties.
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +10.00% and -59.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?